Safety Profile of Lurbinectedin and Patient Selection for Maintenance Therapy

This episode focuses on safety considerations associated with lurbinectedin based maintenance therapy in extensive stage small cell lung cancer. Hematologic adverse effects, including neutropenia and anemia, are reviewed alongside fatigue and other commonly observed toxicities. Strategies for laboratory monitoring, dose modification, and supportive care are outlined within the maintenance context. The discussion also addresses how toxicity risk, performance status, comorbidities, and treatment response after induction influence patient selection. Distinctions between clinically meaningful toxicity and manageable laboratory abnormalities are emphasized. By examining tolerability alongside anticipated benefit, the episode underscores the importance of individualized risk assessment when considering maintenance therapy. These factors are presented within the broader goal of sustaining disease control while maintaining functional status and quality of life in patients with extensive stage small cell lung cancer.